Peptide functionalized liposomes for receptor targeted cancer therapy
Most clinically approved cancer therapies are potent and toxic small molecules that are limited by severe off-target toxicities and poor tumor-specific localization. Over the past few decades, attempts have been made to load chemotherapies into liposomes, which act to deliver the therapeutic agent d...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIP Publishing LLC
2021-03-01
|
| Series: | APL Bioengineering |
| Online Access: | http://dx.doi.org/10.1063/5.0029860 |
| _version_ | 1818644139365892096 |
|---|---|
| author | Matthew R. Aronson Scott H. Medina Michael J. Mitchell |
| author_facet | Matthew R. Aronson Scott H. Medina Michael J. Mitchell |
| author_sort | Matthew R. Aronson |
| collection | DOAJ |
| description | Most clinically approved cancer therapies are potent and toxic small molecules that are limited by severe off-target toxicities and poor tumor-specific localization. Over the past few decades, attempts have been made to load chemotherapies into liposomes, which act to deliver the therapeutic agent directly to the tumor. Although liposomal encapsulation has been shown to decrease toxicity in human patients, reliance on passive targeting via the enhanced permeability and retention (EPR) effect has left some of these issues unresolved. Recently, investigations into modifying the surface of liposomes via covalent and/or electrostatic functionalization have offered mechanisms for tumor homing and subsequently controlled chemotherapeutic delivery. A wide variety of biomolecules can be utilized to functionalize liposomes such as proteins, carbohydrates, and nucleic acids, which enable multiple directions for cancer cell localization. Importantly, when nanoparticles are modified with such molecules, care must be taken as not to inactivate or denature the ligand. Peptides, which are small proteins with <30 amino acids, have demonstrated the exceptional ability to act as ligands for transmembrane protein receptors overexpressed in many tumor phenotypes. Exploring this strategy offers a method in tumor targeting for cancers such as glioblastoma multiforme, pancreatic, lung, and breast based on the manifold of receptors overexpressed on various tumor cell populations. In this review, we offer a comprehensive summary of peptide-functionalized liposomes for receptor-targeted cancer therapy. |
| first_indexed | 2024-12-17T00:10:06Z |
| format | Article |
| id | doaj.art-b952dad308de4afb83b36f5cc521b811 |
| institution | Directory Open Access Journal |
| issn | 2473-2877 |
| language | English |
| last_indexed | 2024-12-17T00:10:06Z |
| publishDate | 2021-03-01 |
| publisher | AIP Publishing LLC |
| record_format | Article |
| series | APL Bioengineering |
| spelling | doaj.art-b952dad308de4afb83b36f5cc521b8112022-12-21T22:10:50ZengAIP Publishing LLCAPL Bioengineering2473-28772021-03-0151011501011501-1110.1063/5.0029860Peptide functionalized liposomes for receptor targeted cancer therapyMatthew R. Aronson0Scott H. Medina1Michael J. Mitchell2 Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USAMost clinically approved cancer therapies are potent and toxic small molecules that are limited by severe off-target toxicities and poor tumor-specific localization. Over the past few decades, attempts have been made to load chemotherapies into liposomes, which act to deliver the therapeutic agent directly to the tumor. Although liposomal encapsulation has been shown to decrease toxicity in human patients, reliance on passive targeting via the enhanced permeability and retention (EPR) effect has left some of these issues unresolved. Recently, investigations into modifying the surface of liposomes via covalent and/or electrostatic functionalization have offered mechanisms for tumor homing and subsequently controlled chemotherapeutic delivery. A wide variety of biomolecules can be utilized to functionalize liposomes such as proteins, carbohydrates, and nucleic acids, which enable multiple directions for cancer cell localization. Importantly, when nanoparticles are modified with such molecules, care must be taken as not to inactivate or denature the ligand. Peptides, which are small proteins with <30 amino acids, have demonstrated the exceptional ability to act as ligands for transmembrane protein receptors overexpressed in many tumor phenotypes. Exploring this strategy offers a method in tumor targeting for cancers such as glioblastoma multiforme, pancreatic, lung, and breast based on the manifold of receptors overexpressed on various tumor cell populations. In this review, we offer a comprehensive summary of peptide-functionalized liposomes for receptor-targeted cancer therapy.http://dx.doi.org/10.1063/5.0029860 |
| spellingShingle | Matthew R. Aronson Scott H. Medina Michael J. Mitchell Peptide functionalized liposomes for receptor targeted cancer therapy APL Bioengineering |
| title | Peptide functionalized liposomes for receptor targeted cancer therapy |
| title_full | Peptide functionalized liposomes for receptor targeted cancer therapy |
| title_fullStr | Peptide functionalized liposomes for receptor targeted cancer therapy |
| title_full_unstemmed | Peptide functionalized liposomes for receptor targeted cancer therapy |
| title_short | Peptide functionalized liposomes for receptor targeted cancer therapy |
| title_sort | peptide functionalized liposomes for receptor targeted cancer therapy |
| url | http://dx.doi.org/10.1063/5.0029860 |
| work_keys_str_mv | AT matthewraronson peptidefunctionalizedliposomesforreceptortargetedcancertherapy AT scotthmedina peptidefunctionalizedliposomesforreceptortargetedcancertherapy AT michaeljmitchell peptidefunctionalizedliposomesforreceptortargetedcancertherapy |